Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Next Previous
Trial Profile

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budigalimab (Primary) ; Livmoniplimab (Primary) ; Carboplatin; Cisplatin; Pembrolizumab; Pemetrexed
  • Indications Anaplastic large cell lymphoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms LIVIGNO-4
  • Sponsors AbbVie

Most Recent Events

  • 23 Feb 2026 Status changed from active, no longer recruiting to recruiting.
  • 20 Jan 2026 Status changed from recruiting to active, no longer recruiting.
  • 28 Nov 2024 Planned End Date changed from 8 Oct 2031 to 1 Oct 2031.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top